8.03

3.08% 0.24

Relay Therapeutics Inc (RLAY)

Overview News Price History Option Chain Financials Why RLAY Down? Discussions Forecast

Relay Therapeutics Inc stock is traded at $8.03, with a volume of 2.84M. It is up +3.08% in the last 24 hours and up +30.15% over the past month. Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

Previous Close:

$7.79

Open:

$8.6

24h Volume:

2.84M

Relative Volume:

1.44

Market Cap:

$1.39B

Revenue:

$25.55M

Net Income/Loss:

$-341.97M

P/E Ratio:

-2.8679

EPS:

-2.8

Net Cash Flow:

$-304.44M

1W Performance:

+4.56%

1M Performance:

+30.15%

6M Performance:

+132.75%

1Y Performance:

+67.99%

1-Day Range:

$7.71

$8.70

1-Week Range:

$7.42

$8.70

52-Week Range:

$1.775

$8.70

Relay Therapeutics Inc Stock (RLAY) Company Profile

Name

Relay Therapeutics Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

617-370-8837

Address

60 HAMPSHIRE STREET, CAMBRIDGE

Employee

197

Twitter

Next Earnings Date

2025-02-21

Latest SEC Filings

RLAY's Discussions on Twitter

Compare RLAY with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RLAY Relay Therapeutics Inc	8.03	1.35B	25.55M	-341.97M	-304.44M	-2.80
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-04-25	Resumed	Guggenheim	Buy
Apr-17-25	Initiated	Wells Fargo	Equal Weight
Sep-10-24	Resumed	Goldman	Buy
Sep-10-24	Upgrade	Jefferies	Hold → Buy
Sep-10-24	Downgrade	Oppenheimer	Outperform → Perform
May-10-24	Upgrade	Barclays	Equal Weight → Overweight
Apr-20-23	Upgrade	Jefferies	Underperform → Hold
Apr-19-23	Upgrade	Raymond James	Outperform → Strong Buy
Apr-13-23	Initiated	Raymond James	Outperform
Feb-03-23	Initiated	Oppenheimer	Outperform
Sep-30-22	Initiated	Barclays	Equal Weight
Sep-02-22	Initiated	Stifel	Buy
Jun-06-22	Initiated	Jefferies	Underperform
Feb-01-22	Initiated	Berenberg	Buy
Jul-21-21	Initiated	BofA Securities	Buy
Dec-15-20	Reiterated	H.C. Wainwright	Buy
Dec-08-20	Initiated	JMP Securities	Mkt Outperform
Nov-05-20	Initiated	H.C. Wainwright	Buy
Aug-10-20	Initiated	Cowen	Outperform
Aug-10-20	Initiated	Goldman	Buy
Aug-10-20	Initiated	Guggenheim	Buy
Aug-10-20	Initiated	JP Morgan	Neutral

View All

Relay Therapeutics Inc Stock (RLAY) Latest News

Dec 13, 2025

Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares - AOL.com

Dec 13, 2025

Why Is Relay Therapeutics Stock Gaining Friday?Relay Therapeutics (NASDAQ:RLAY) - Benzinga

Dec 12, 2025

RLAY Stock Receives Analyst Upgrade and Price Target Boost | RLA - GuruFocus

Dec 12, 2025

Relay Therapeutics stock hits 52-week high at 8.62 USD By Investing.com - Investing.com South Africa

Dec 12, 2025

Relay Therapeutics stock hits 52-week high at 8.62 USD - Investing.com

Dec 12, 2025

Relay Therapeutics Reports 'Robust Activity' in Study of Zovegalisib to Treat Breast Cancer - marketscreener.com

Dec 12, 2025

Relay Therapeutics (RLAY) Shares New Data from Zovegalisib Study - GuruFocus

Dec 12, 2025

Relay Therapeutics unveils efficacy subset analysis for zovegalisib at SABCS25 - Traders Union

Dec 12, 2025

Relay Therapeutics Announces Efficacy Subset Analysis of - GlobeNewswire

Dec 12, 2025

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Holdings in Relay Therapeutics, Inc. $RLAY - MarketBeat

Dec 12, 2025

149,701 Shares in Relay Therapeutics, Inc. $RLAY Acquired by HighVista Strategies LLC - MarketBeat

Dec 12, 2025

Here's Why Relay Therapeutics, Inc. (RLAY) is a Great Momentum Stock to Buy - MSN

Dec 12, 2025

Dec 11, 2025

Norges Bank Buys Shares of 835,874 Relay Therapeutics, Inc. $RLAY - MarketBeat

Dec 11, 2025

Dec 10, 2025

Diadema Partners LP Has $151,000 Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat

Dec 10, 2025

Dec 08, 2025

Mixed Investor Sentiment Surrounds Relay Therapeutics Stock - AD HOC NEWS

Dec 08, 2025

Dec 07, 2025

Growth Value: Why Relay Therapeutics Inc stock could outperform in 20252025 Market Trends & Technical Pattern Recognition Alerts - moha.gov.vn

Dec 07, 2025

JPMorgan Chase & Co. Reduces Stock Holdings in Relay Therapeutics, Inc. $RLAY - MarketBeat

Dec 07, 2025

Dec 06, 2025

Relay Therapeutics (NASDAQ:RLAY) Shares Down 5%What's Next? - MarketBeat

Dec 06, 2025